CML: First-line Generic Imatinib May Be Inferior to Branded Imatinib

Share this content:
First-line therapy with generic imatinib in chronic myeloid leukemia is associated with poorer outcomes compared with branded imatinib (Gleevec).
First-line therapy with generic imatinib in chronic myeloid leukemia is associated with poorer outcomes compared with branded imatinib (Gleevec).

First-line therapy with generic imatinib in chronic myeloid leukemia (CML) is associated with poorer outcomes compared with branded imatinib (Gleevec). Generic imatinib as second-line therapy does not, however, have a negative effect on outcomes, according to a study published in Clinical Lymphoma, Myeloma & Leukemia.1

The expiration of Novartis Pharmaceutical's patent on imatinib mesylate led to recent approvals of generic products in numerous countries, offering a lower cost alternative for the treatment of patients with CML. But the long-term clinical outcomes in patients treated with generics remain unclear.

To evaluate outcomes of patients treated with first-line and second-line generic imatinib, investigators analyzed data from 41 patients treated between 2013 and 2016.

Of those, 27 were newly diagnosed patients receiving generic imatinib as first-line therapy and 14 were patients who received second-line generic imatinib after switching from frontline Gleevec.

With a median follow-up of 16 months, 85% of patients given first-line generic imatinib were alive at 36 months and 81% had achieved a complete cytogenetic response. Nearly half (48%) achieved a major molecular response by 24 months.

Fifty-two percent of patients who received generic imatinib as first-line therapy switched to nilotinib due to disease progression and intolerable side effects.

Among those who switched to generic imatinib after first-line Gleevec, 93% of patients sustained cytogenetic and molecular response at 36 months of generic treatment. The 1 patient who lost complete cytogenetic response and major molecular response was on Gleevec for 5 months before switching to generic imatinib.

RELATED: Smoking May Increase Risk of Death in Patients With CML

The authors concluded that first-line generic imatinib demonstrated suboptimal efficacy with branded imatinib, while second-line generic therapy did not have a negative impact on patient outcomes.

Reference

  1. Islamagic E, Hasic A, Kurtovic S, et al. The efficacy of generic imatinib as first- and second-line therapy: three year follow-up of chronic myeloid leukemia patients. Clin Lymphoma Myeloma Leuk. 2017 Feb 16. doi: 10.1016/j.clml.2017.02.001 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters